---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Naxitamab-gqgk - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/naxitamab-gqgk
version: v1
---

# Naxitamab-gqgk - NCI

# Naxitamab-gqgk

Placeholder slot

(nak-SIH-tuh-mab)

This page contains brief information about naxitamab-gqgk
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Danyelza

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29a80c6b-8bad-4650-8c7f-f18490c868ec&audience=consumer)

## Use in Cancer

Naxitamab-gqgk
is approved to be used with [granulocyte-macrophage colony-stimulating factor](/Common/PopUps/popDefinition.aspx?id=423043&version=Patient&language=English) (GM-CSF) to treat:

- **[Neuroblastoma](/Common/PopUps/popDefinition.aspx?id=45418&version=Patient&language=English)** in the bone or [bone marrow](/Common/PopUps/popDefinition.aspx?id=45622&version=Patient&language=English) that is [high risk](/Common/PopUps/popDefinition.aspx?id=45079&version=Patient&language=English) and has [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) (come back) or is [refractory](/Common/PopUps/popDefinition.aspx?id=45863&version=Patient&language=English) (does not respond to treatment). It is used in children aged 1 year and older and adults who had at least a [partial response](/Common/PopUps/popDefinition.aspx?id=45819&version=Patient&language=English) to other types of treatment.

This use is approved under FDAâ€™s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that naxitamab-gqgk provides a clinical benefit in these patients.

## More About Naxitamab-gqgk

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778692) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Naxitamab-gqgk](https://medlineplus.gov/druginfo/meds/a621005.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Naxitamab-gqgk](https://www.cancer.gov/research/participate/clinical-trials/intervention/C123428) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
